Natural Product (NP) Details
General Information of the NP (ID: NP4593) | |||||
---|---|---|---|---|---|
Name |
Fosfomycin
|
||||
Synonyms |
FOSFOMYCIN; phosphomycin; Phosphonomycin; 23155-02-4; Fosfonomycin; Fosfocina; Monurol; Veramina; Fosfomicina; Fosfomycine; Fosfomycinum; Antibiotic 833A; [(2R,3S)-3-methyloxiran-2-yl]phosphonic acid; Phosphonic acid, (3-methyloxiranyl)-, (2R-cis)-; UNII-2N81MY12TE; (2R-cis)-(3-Methyloxiranyl)phosphonic acid; (1R,2S)-epoxypropylphosphonic acid; Phosphonemycin; L-cis-1,2-epoxypropylphosphonic acid; (-)-(1R,2S)-(1,2-Epoxypropyl)phosphonic acid; CHEMBL1757; Fosfomycin disodium salt; 2N81MY12TE; CHEBI:28915; FCM; Phosphonic acid, (1,2-epoxypropyl)-, (1R,2S)-(-)-; cis-(1R,2S)-epoxypropylphosphonic acid; 1R-cis-(1,2-epoxypropyl)phosphonic acid; ((2R,3S)-3-methyloxiran-2-yl)phosphonic acid; Fosfomicin; Infectophos; 1,2-EPOXYPROPYLPHOSPHONIC ACID; Levo-phosphonomycin; Fosfomycin (USAN/INN); Fosfomycine [INN-French]; Fosfomycinum [INN-Latin]; Fosfomicina [INN-Spanish]; Fosfomycin [USAN:INN:BAN]; J01XX01; EINECS 245-463-1; MK-955; BRN 1680831; 883A; Fosfomycin (compound 1); Fosfomycinfor culture media; SCHEMBL50951; BIDD:GT0448; BRN 1680831, Fosfocina; ZTI-01; DTXSID4048480; GTPL10813; BCP24891; ZINC1530427; BDBM50024894; cis-(2-Methyloxiranyl)-phosphonic acid; DB00828; (2R,3S)-3-methyloxiran-2-ylphosphonate; 25030-76-6; (1R, 2S)-1,2-epoxypropyl-phosphonic acid; FT-0774116; (2R,3S)-3-methyloxiran-2-ylphosphonic acid; (3-Methyl-oxiranyl)-phosphonic acid(Na salt); C06454; D04253; Q183554; W-107422; BRD-K81101512-234-01-9; Phosphonic acid, P-[(2R,3S)-3-methyl-2-oxiranyl]-; 6F066DFF-696A-4A94-AF78-A28430EBE5BA
Click to Show/Hide
|
||||
Species Origin | Streptomyces fradiae ... | Click to Show/Hide | |||
Streptomyces fradiae | |||||
Disease | Bacterial infection [ICD-11: 1A00-1C4Z] | Approved | [1] | ||
Structure |
![]() |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C3H7O4P
|
||||
PubChem CID | |||||
Canonical SMILES |
CC1C(O1)P(=O)(O)O
|
||||
InChI |
1S/C3H7O4P/c1-2-3(7-2)8(4,5)6/h2-3H,1H3,(H2,4,5,6)/t2-,3+/m0/s1
|
||||
InChIKey |
YMDXZJFXQJVXBF-STHAYSLISA-N
|
||||
CAS Number |
CAS 23155-02-4
|
||||
ChEBI ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Ciprofloxacin | Bacterial infection | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
In-vitro Model | Shigella flexneri isolates | Microorganism model | Shigella flexneri | |||
Experimental
Result(s) |
Against CIPR S. flexneri isolates, the CIP/FOS combination induced synergy, and increased bacterial killing in vitro and in a simple invertebrate model of infection. | |||||
Linezolid | Bacterial infection | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) |
Combination Info
![]() |
|||||
In-vitro Model | Staphylococcus aureus strains | Microorganism model | Staphylococcus aureus | |||
Experimental
Result(s) |
Linezolid combined with fosfomycin at 4x MIC showed the best synergistic antibacterial effect, and this effect was retained after 24 hours. | |||||
Meropenem | Bacterial infection | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [4] | |||||
Detail(s) |
Combination Info
![]() |
|||||
In-vitro Model | Pseudomonas aeruginosa PAO1 | Microorganism model | Pseudomonas aeruginosa | |||
Experimental
Result(s) |
The combination of fosfomycin plus meropenem is synergistic for pseudomonas aeruginosa PAO1 in a hollow-fiber infection model. | |||||
Rifampicin | HIV-infected patients with tuberculosis | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [5] | |||||
Detail(s) |
Combination Info
![]() |
|||||
In-vivo Model | Clinical trial | |||||
Experimental
Result(s) |
In patients with implanted foreign devices, combination therapy was associated with a better long-term outcome. | |||||
N-acetylcysteine | Liver disease | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [6] | |||||
Detail(s) |
Combination Info
![]() |
|||||
In-vitro Model | Escherichia coli strains | Microorganism model | Escherichia coli | |||
Experimental
Result(s) |
Fosfomycin and NAC at concentrations achievable in urine displayed a synergistic effect promoting both the formation of biofilms and reduction of sessile cell viability. | |||||
Ceftazidime + Avibactam | Click to Show/Hide the Molecular Data of This Drug | |||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [7] | |||||
Detail(s) |
Combination Info
![]() |
|||||
In-vitro Model | Klebsiella pneumoniae clinical strains | Microorganism model | Klebseilla pneumoniae | |||
Experimental
Result(s) |
The combinations of ceftazidime-avibactam with ertapenem, and ceftazidime-avibactam with tigecycline were able to reduce the MIC to less than the susceptibility breakpoint in all KPC- and OXA-48-producing K. pneumoniae. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Bacterial Enoylpyruvate transferas (Bact murA) | Molecule Info | [8] |
